BioPharma Semax 5mg

Often stacked with: Selank 10mg

Discover Semax 5mg, a synthetic heptapeptide analog of the adrenocorticotropic hormone fragment ACTH(4-10). With the sequence Met-Glu-His-Phe-Pro-Gly-Pro, Semax was developed in Russia and has been used clinically there since the 1990s for neuroprotection, cognitive support, and recovery after ischemic events. The stabilizing Pro-Gly-Pro extension significantly improves stability compared with the native ACTH fragment while eliminating hormonal (corticotropic) activity.

The 5mg vial strength is a common research and multi-dose format suitable for laboratory protocols investigating brain-derived neurotrophic factor (BDNF) pathways, cognitive performance, and neuronal resilience.

Key Research Areas of Interest for Semax 5mg

•  Upregulation of BDNF and nerve growth factor (NGF) expression in the hippocampus and cortex.

•  Modulation of dopaminergic and serotonergic neurotransmission linked to attention, focus, and mood.

•  Neuroprotective effects studied in models of ischemic stroke and cerebral hypoperfusion.

•  Support for cognitive function under fatigue, stress, or recovery conditions.

•  Research interest in optic nerve disorders and adaptive responses to extreme or demanding environments (based on Russian clinical experience).

•  Melanocortin receptor (particularly MC4R) engagement relevant to learning and memory circuits.

How Semax Works

Semax retains the neurotrophic core of ACTH(4-10) without stimulating adrenal steroid production. Primary documented mechanisms include:

•  Rapid increase in BDNF mRNA and protein levels, supporting synaptic plasticity and neuronal survival.

•  Modulation of monoamine (dopamine and serotonin) systems.

•  Activation of melanocortin receptors and downstream MAPK/ERK signaling.

•  Potential anti-inflammatory and antioxidant contributions in neural tissue.

These actions make Semax a frequently studied tool in nootropic and neuroprotective research.

Administration & Protocol Considerations

In Russian pharmaceutical practice, Semax is most commonly delivered intranasally (0.1% solution for cognitive use; higher concentrations for acute neurological indications). Typical research and clinical ranges for cognitive support are 200–600 mcg per day, often divided into 2–3 administrations. The 5mg research vial allows flexible reconstitution for laboratory or clinician-supervised protocols. Subcutaneous routes have also been explored in research settings.

Semax is not FDA-approved in the United States for any indication. It remains a research compound in most Western jurisdictions (subject to compounding and regulatory developments).

Common Side Effects & Safety Profile

Available data from Russian clinical use and research literature describe a generally favorable tolerability profile. The most frequently noted effects are mild nasal irritation or dryness with intranasal administration. Occasional reports include transient headache, increased vivid dreaming, or mild stimulatory sensations. Serious adverse events appear uncommon at standard doses. Individual responses vary; monitoring is advised in any supervised setting.

Critical Disclaimer: Semax 5mg is intended for laboratory research or use under qualified medical supervision only. It is not an FDA-approved drug in the United States and is not intended to diagnose, treat, cure, or prevent any disease. Not for self-administration without proper training and oversight. Source only from reputable suppliers providing third-party purity testing and Certificates of Analysis. Consult a licensed healthcare professional before any use. Results are not guaranteed.

Advance your cognitive and neuroprotective research with high-purity Semax 5mg. Verify testing documentation and prioritize quality-sourced material for reproducible results.